Physician profile
James Phillips
NPI 1144724170
$2,298.27
in general payments reported to CMS, 2019-2025
23 companies · $301 in 2025
The $301 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $117 · 2022: $733 · 2023: $564 · 2024: $583 · 2025: $301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,448.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,447.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $462.32 | 2022-2024 | |
| Lilly USA, LLC | $261.72 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $242.95 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $237.83 | 2021-2025 | Breztri, Farxiga |
| Exact Sciences Corporation | $175.25 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $139.03 | 2021-2025 | |
| Glaxosmithkline, LLC. | $134.03 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.88 | 2022-2024 | Jardiance, Tradjenta |
| Merck Sharp & Dohme LLC | $74.38 | 2022-2024 | Gardasil 9, Vaxneuvance, Pneumovax 23 |
| Biohaven Pharmaceutical Holding Company LTD. | $69.95 | 2022 | |
| Eisai INC. | $54.91 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.67 | 2022-2023 | |
| Astellas Pharma US INC | $54.33 | 2024-2025 | Veozah |
| Amarin Pharma, INC. | $44.40 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $36.20 | 2021-2025 | Camzyos |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $33.07 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.33 | 2022 | |
| Esperion Therapeutics, INC. | $25.30 | 2025 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $20.72 | 2022 | |
| Amgen INC. | $17.88 | 2023 | Otezla, Repatha |
| Ascensia Diabetes Care US INC. | $14.45 | 2024 | |
| Sanofi Pasteur INC. | $13.99 | 2022 | |
| Biogen, INC. | $12.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.